PROFILPELAJAR.COM

Atrasentan
Clinical data
ATC code	none;
Identifiers
	IUPAC name (2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid;
CAS Number	173937-91-2 ;
PubChem CID	159594;
ChemSpider	140321 ;
UNII	V6D7VK2215;
ChEMBL	ChEMBL9194 ;
ECHA InfoCard	100.206.784
Chemical and physical data
Formula	C29H38N2O6
Molar mass	510.631 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)[C@H]4[C@H](c1ccc(OC)cc1)N(CC(=O)N(CCCC)CCCC)C[C@@H]4c2ccc3OCOc3c2;
	InChI InChI=1S/C29H38N2O6/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34)/t23-,27-,28+/m1/s1 ; Key:MOTJMGVDPWRKOC-QPVYNBJUSA-N ;
	(what is this?) (verify)

Atrasentan is an experimental drug that is being studied for the treatment of various types of cancer,^[1] including non-small cell lung cancer.^[2] It is also being investigated as a therapy for diabetic kidney disease.^[3]

It is an endothelin receptor antagonist selective for subtype A (ET_A). While other drugs of this type (sitaxentan, ambrisentan) exploit the vasoconstrictive properties of endothelin and are mainly used for the treatment of pulmonary arterial hypertension, atrasentan blocks endothelin induced cell proliferation.^{[citation needed]}

Clinical trials

Atrasentan failed a phase 3 trial for prostate cancer in patients unresponsive to hormone therapy.^[4] A second trial confirmed this finding.^[5]

In April 2014, de Zeeuw et al. showed that 0.75 mg and 1.25 mg of atrasentan reduced urinary albumin by 35 and 38% respectively with modest side effects. Patients also had decreased home blood pressures (but no change in office readings) decrease total cholesterol and LDL. Patients in the 1.25 mg dose group had increased weight gain which was presumably due to increased edema and had to withdraw from the study more than the placebo or 0.75 mg dose group.^[6] Reductions in proteinuria have been associated with beneficial patient outcomes in diabetic kidney disease with other interventions but is not an accepted end-point by the FDA.^{[citation needed]}

In 2013, SONAR trial^[7] was initiated to determine if atrasentan reduces kidney failure in diabetic kidney disease.^[8]

In 2024, the phase 3 ALIGN trial found atrasentan to be effective in reducing proteinuria in patients with IgA nephropathy.^[9]